This compares with our net accounts receivable bonds of $1,198,000,000 at the end of quarter 2, 2024. DSO was 52 days at September 30, 2024, an increase of 3 days from quarter 3, 2023 and an increase of one day from June 30, 2024. Cash from operating activities in the quarter was $402,700,000 and free cash flow was $359,400,000 in the quarter, an increase of 15% on a year over year basis. We saw a nice improvement in cash collections in quarter 3 despite the ongoing dynamic is present with our customers, particularly large pharma organizations, looking to hold on to cash longer and seeking competitive credit terms. Despite this dynamic, we remain on track to achieve our original full year guidance of free cash flow of circa $1,100,000,000 At September 30, 2024, cash totaled $695,500,000 and debt totaled $3,400,000,000 leaving a net debt position of $2,700,000,000 This compares to net debt of $2,900,000,000 at June 30, 2024 and net debt of $3,700,000,000 at September 30, 2023.